Sanofi Says Decided In February To Produce Hydroxychloroquine At Maximum Capacity, Says Company Operating At More Than 93% Capacity, Keeps Building Inventory; Shared Hydroxychloroquine Data With Other Companies To Ensure Best Possible Patient Access